JPRN-jRCT2080223678
Completed
Phase 3
A phase 3 clinical trial of duloxetine in children and adolescents with depressive disorder
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shionogi & Co., Ltd.
- Enrollment
- 149
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who diagnosed with major depressive disorder or persistent depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM\-5\) and completely meet the criteria of major depressive episode. And et al.
Exclusion Criteria
- •Patients who have allergies to two or more medicines or have a history of severe allergic reactions with medicines. Patients who have participated in a clinical study or a clinical investigation of duloxetine and have previously received study drugs. And et al.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2EUCTR2017-003328-56-GBniversity College London Comprehensive Clinical Trials Unit1,180
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaHER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMedDRA version: 21.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001757-27-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,542
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaHER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaMedDRA version: 27.0Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001757-27-IEMerck Sharp & Dohme LLC1,542
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaEUCTR2018-001757-27-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.1,542
Active, not recruiting
Phase 1
Pembrolizumab/placebo plus chemotherapy as first-line therapy in participants with HER2 negative advanced gastric or GEJ adenocarcinomaEUCTR2018-001757-27-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,542